がんワクチン市場 - 世界の産業規模、シェア、動向、機会、予測：適応症タイプ別、ワクチンタイプ別、技術タイプ別、地域別、競合、2020年～2030年

がんワクチンの世界市場は、2024年に83億2,000万米ドルと評価され、予測期間には141億5,000万米ドルに達し、2030年までのCAGRで9.21%の成長が予測されています。

がんワクチンとは、免疫系を刺激してがん細胞を認識・攻撃させることを目的とした免疫療法の一種です。感染症を予防する従来のワクチンとは異なり、がんワクチンは体内の免疫反応を活用することでがんを治療または予防するように設計されています。がんワクチンのコンセプトは、がん細胞の表面にある特定の分子や抗原を免疫系に提示することです。これらの抗原は多くの場合、がん細胞特有のものであったり、正常細胞に比べてがん細胞上に多く存在します。免疫系をこれらの抗原にさらすことで、健康な細胞は温存しつつ、がん細胞を識別・破壊するよう免疫細胞を誘導することを目的としています。

免疫チェックポイント阻害剤やCAR-T細胞療法などの免疫療法の成功により、がんワクチンの可能性に対する関心と信頼が高まっています。これらの進歩は、がん細胞を標的とする免疫系の役割を浮き彫りにし、がんワクチンへのさらなる研究と投資を促進しています。ゲノミクス、プロテオミクス、バイオインフォマティクスの進歩は、腫瘍生物学のより深い理解と潜在的なワクチン標的の同定を可能にしました。これらの技術革新は、がんワクチンの発見と開発を加速させています。ワクチンと免疫チェックポイント阻害剤や化学療法など、異なる治療法を組み合わせるというコンセプトが支持を集めています。併用療法は治療効果を高め、耐性メカニズムを克服する可能性を秘めています。様々な世界ヘルス組織やイニシアチブが、がんの予防と治療の重要性を強調しています。これらのイニシアチブは、研究開発に対する認識と資金提供の増加に寄与しています。

主な市場促進要因

免疫チェックポイント阻害薬の需要拡大

主な市場課題

がん免疫学の複雑性

主要市場動向

共同研究およびパートナーシップ

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 臨床試験分析

• 進行中の臨床試験
• 完了した臨床試験
• 中止された臨床試験
• 開発フェーズ別パイプラインの内訳
• パイプラインのステータス別内訳
• パイプラインの内訳（研究タイプ別）
• 地域別パイプライン内訳
• 臨床試験ヒートマップ

第6章 世界のがんワクチン市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 適応症タイプ別（前立腺がん、メラノーマ、膀胱がん、子宮頸がん）
  • ワクチンタイプ別（予防用がんワクチン、治療用がんワクチン）
  • 技術タイプ別（組換えがんワクチン、全細胞がんワクチン、ウイルスベクター・DNAがんワクチン）
  • 企業別（2024）
  • 地域別
• 市場マップ

第7章 北米のがんワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 欧州のがんワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第9章 アジア太平洋地域のがんワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第10章 南米のがんワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第11章 中東・アフリカのがんワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第12章 市場力学

• 促進要因
• 課題

第13章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第14章 PESTEL分析

第15章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第16章 競合情勢

• Merck & Co., Inc.
• GSK plc
• Dendreon Pharmaceuticals LLC.
• Dynavax Technologies.
• Ferring B.V.
• Amgen, Inc.
• Moderna, Inc.
• Sanofi SA
• AstraZeneca Pharmaceuticals LP
• Bristol-Myers Squibb Company

第17章 戦略的提言

第18章 調査会社について・免責事項

Global Cancer Vaccine Market was valued at USD 8.32 billion in 2024 and is expected to reach USD 14.15 billion in the forecast period with a CAGR of 9.21% through 2030. A cancer vaccine is a type of immunotherapy that aims to stimulate the immune system to recognize and attack cancer cells. Unlike traditional vaccines that prevent infectious diseases, cancer vaccines are designed to treat or prevent cancer by leveraging the body's own immune response. The concept behind cancer vaccines is to present the immune system with specific molecules or antigens found on the surface of cancer cells. These antigens are often unique to cancer cells or are more abundant on cancer cells compared to normal cells. By exposing the immune system to these antigens, the goal is to prime immune cells to identify and destroy cancer cells while sparing healthy cells.

The success of immunotherapies, including immune checkpoint inhibitors and CAR-T cell therapies, has generated interest and confidence in the potential of cancer vaccines. These advancements have highlighted the role of the immune system in targeting cancer cells, driving further research and investment in cancer vaccines. Advances in genomics, proteomics, and bioinformatics have enabled a deeper understanding of tumor biology and the identification of potential vaccine targets. These technological innovations have accelerated the discovery and development of cancer vaccines. The concept of combining different treatment modalities, such as vaccines with immune checkpoint inhibitors or chemotherapy, has gained traction. Combination therapies have the potential to enhance treatment efficacy and overcome resistance mechanisms. Various global health organizations and initiatives have highlighted the importance of cancer prevention and treatment. These initiatives contribute to increased awareness and funding for cancer vaccine research and development.

Key Market Drivers

Growing Demand of Immune Checkpoint Inhibitors

Immune checkpoint inhibitors have become a cornerstone in modern cancer immunotherapy, offering a transformative approach to treating malignancies that were once considered difficult to manage. These drugs work by targeting checkpoint proteins such as PD-1, PD-L1, and CTLA-4, which act as regulatory switches on immune cells. By blocking these proteins, immune checkpoint inhibitors restore the immune system's ability to detect and destroy cancer cells. According to a 2024 study published in Nature Reviews Drug Discovery, over 40 FDA-approved indications now exist for checkpoint inhibitors, covering more than 20 cancer types. This rising number of approvals demonstrates the expanding clinical utility and acceptance of these therapies.

One of the most compelling aspects of immune checkpoint inhibitors is their ability to produce durable and, in some cases, complete responses in patients with advanced-stage cancers. Recent data from the American Association for Cancer Research (AACR) reveals that five-year survival rates for patients with metastatic melanoma have improved from under 10% to nearly 35% with checkpoint inhibitor therapy. These outcomes are especially significant for patients who had exhausted conventional treatment options. The success stories from checkpoint inhibitor therapies have intensified the focus on immunotherapeutic approaches, including cancer vaccines, which can potentially synergize with these agents to produce even more powerful immune responses.

Checkpoint inhibitors are increasingly being used in combination therapy regimens to overcome resistance mechanisms and broaden their efficacy. Clinical trials are currently exploring over 1,000 combination strategies globally, many of which involve pairing checkpoint inhibitors with cancer vaccines. The rationale behind such combinations lies in their complementary mechanisms-vaccines prime the immune system to recognize tumor-specific antigens, while checkpoint inhibitors unleash T cells to eliminate the identified cancer cells. This integrated approach is driving deeper and more sustained responses, particularly in tumors with low immunogenicity that may not respond well to monotherapies.

The growing demand for immune checkpoint inhibitors is not only driving innovation in therapeutic strategies but also reinforcing the role of cancer vaccines as a critical component of immuno-oncology pipelines. As researchers strive to enhance treatment precision and personalization, vaccines are being developed to target neoantigens identified through next-generation sequencing. The success and continued development of checkpoint inhibitors have built a robust foundation of scientific, clinical, and commercial support for immunotherapies. This momentum is expected to further accelerate interest and investment in cancer vaccines, which are increasingly seen as essential components of comprehensive cancer immunotherapy regimens.

Key Market Challenges

Complexity of Cancer Immunology

Cancer immunology involves the intricate interplay between cancer cells and the immune system, and understanding and manipulating this interaction for therapeutic purposes is no small task. Cancers are highly heterogeneous, meaning that they can have diverse populations of cells with distinct genetic and antigenic profiles. Identifying the right antigens to target with a vaccine becomes challenging, as a one-size-fits-all approach may not be effective. Cancer cells can develop mechanisms to evade immune detection and attack. They can downregulate antigens, express inhibitory molecules, or create an immunosuppressive microenvironment. Developing vaccines that overcome these strategies is complex.

Selecting the most appropriate antigens for targeting is a challenge. Not all tumor antigens are equally effective at inducing a strong immune response, and the wrong choice can result in inadequate therapeutic outcomes. The immune system is designed to avoid attacking healthy cells. Overcoming immune tolerance mechanisms while avoiding autoimmune reactions is a delicate balance that must be considered in vaccine design. Ensuring that the vaccine itself is immunogenic and can stimulate a robust immune response is crucial. Some tumors may have a suppressive effect on the immune system, making it difficult to generate a response. Identifying reliable biomarkers that predict which patients will respond positively to a cancer vaccine is a challenge. Responders and non-responders can have varied immune profiles, and finding consistent predictive markers can be difficult.

Key Market Trends

Collaborations and Partnerships

The complex nature of cancer research, vaccine development, and clinical trials often necessitates collaboration among various stakeholders to accelerate progress, share expertise, and pool resources. Developing effective cancer vaccines requires expertise in various fields, including immunology, oncology, virology, genetics, and more. Collaborations allow researchers and organizations to bring together experts from different disciplines to tackle complex challenges. Collaborations enable the sharing of resources, such as research facilities, laboratories, equipment, and reagents. This can reduce costs and accelerate the research and development process. Partnerships provide access to cutting-edge technologies and platforms that individual organizations might not have. This can streamline vaccine development and improve research capabilities.

In-depth understanding of cancer biology and immunology requires access to vast amounts of data. Collaborations allow for data sharing, analysis, and integration, facilitating better insights into vaccine targets and mechanisms. Running clinical trials for cancer vaccines often requires collaboration among multiple institutions and hospitals. Partnerships can facilitate patient recruitment, trial logistics, and data collection. Collaborations can attract funding from various sources, including government agencies, private investors, philanthropic organizations, and venture capital firms. This financial support can drive research and development efforts. Partnerships with pharmaceutical companies can help bring cancer vaccines to market more effectively, leveraging established distribution channels, sales teams, and marketing resources.

Key Market Players

• Merck & Co., Inc.
• GSK plc
• Dendreon Pharmaceuticals LLC.
• Dynavax Technologies.
• Ferring B.V.
• Amgen, Inc.
• Moderna, Inc.
• Sanofi SA
• AstraZeneca Pharmaceuticals LP
• Bristol-Myers Squibb Company

Report Scope:

In this report, the Global Cancer Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cancer Vaccine Market, By Indication Type:

• Prostate Cancer
• Melanoma
• Bladder Cancer
• Cervical Cancer

Cancer Vaccine Market, By Vaccine Type:

• Preventive Cancer Vaccines
• Therapeutic Cancer Vaccines

Cancer Vaccine Market, By Technology Type:

• Recombinant Cancer Vaccines
• Whole-Cell Cancer Vaccines
• Viral Vector and DNA Cancer Vaccines

Cancer Vaccine Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cancer Vaccine Market.

Available Customizations:

Global Cancer Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trials Analysis

• 5.1. Ongoing Clinical Trials
• 5.2. Completed Clinical Trials
• 5.3. Terminated Clinical Trials
• 5.4. Breakdown of Pipeline, By Development Phase
• 5.5. Breakdown of Pipeline, By Status
• 5.6. Breakdown of Pipeline, By Study Type
• 5.7. Breakdown of Pipeline, By Region
• 5.8. Clinical Trials Heat Map

6. Global Cancer Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indication Type (Prostate Cancer, Melanoma, Bladder Cancer, Cervical Cancer
  • 6.2.2. By Vaccine Type (Preventive Cancer Vaccines, Therapeutic Cancer Vaccines)
  • 6.2.3. By Technology Type (Recombinant Cancer Vaccines, Whole-Cell Cancer Vaccines, Viral Vector and DNA Cancer Vaccines)
  • 6.2.4. By Company (2024)
  • 6.2.5. By Region
• 6.3. Market Map

7. North America Cancer Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication Type
  • 7.2.2. By Vaccine Type
  • 7.2.3. By Technology Type
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Cancer Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indication Type
      • 7.3.1.2.2. By Vaccine Type
      • 7.3.1.2.3. By Technology Type
  • 7.3.2. Mexico Cancer Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indication Type
      • 7.3.2.2.2. By Vaccine Type
      • 7.3.2.2.3. By Technology Type
  • 7.3.3. Canada Cancer Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indication Type
      • 7.3.3.2.2. By Vaccine Type
      • 7.3.3.2.3. By Technology Type

8. Europe Cancer Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication Type
  • 8.2.2. By Vaccine Type
  • 8.2.3. By Technology Type
  • 8.2.4. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. France Cancer Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication Type
      • 8.3.1.2.2. By Vaccine Type
      • 8.3.1.2.3. By Technology Type
  • 8.3.2. Germany Cancer Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication Type
      • 8.3.2.2.2. By Vaccine Type
      • 8.3.2.2.3. By Technology Type
  • 8.3.3. United Kingdom Cancer Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication Type
      • 8.3.3.2.2. By Vaccine Type
      • 8.3.3.2.3. By Technology Type
  • 8.3.4. Italy Cancer Vaccine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Indication Type
      • 8.3.4.2.2. By Vaccine Type
      • 8.3.4.2.3. By Technology Type
  • 8.3.5. Spain Cancer Vaccine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Indication Type
      • 8.3.5.2.2. By Vaccine Type
      • 8.3.5.2.3. By Technology Type

9. Asia-Pacific Cancer Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication Type
  • 9.2.2. By Vaccine Type
  • 9.2.3. By Technology Type
  • 9.2.4. By Country
• 9.3. Asia-Pacific: Country Analysis
  • 9.3.1. China Cancer Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication Type
      • 9.3.1.2.2. By Vaccine Type
      • 9.3.1.2.3. By Technology Type
  • 9.3.2. India Cancer Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication Type
      • 9.3.2.2.2. By Vaccine Type
      • 9.3.2.2.3. By Technology Type
  • 9.3.3. South Korea Cancer Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication Type
      • 9.3.3.2.2. By Vaccine Type
      • 9.3.3.2.3. By Technology Type
  • 9.3.4. Japan Cancer Vaccine Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Indication Type
      • 9.3.4.2.2. By Vaccine Type
      • 9.3.4.2.3. By Technology Type
  • 9.3.5. Australia Cancer Vaccine Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Indication Type
      • 9.3.5.2.2. By Vaccine Type
      • 9.3.5.2.3. By Technology Type

10. South America Cancer Vaccine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indication Type
  • 10.2.2. By Vaccine Type
  • 10.2.3. By Technology Type
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Cancer Vaccine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indication Type
      • 10.3.1.2.2. By Vaccine Type
      • 10.3.1.2.3. By Technology Type
  • 10.3.2. Argentina Cancer Vaccine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indication Type
      • 10.3.2.2.2. By Vaccine Type
      • 10.3.2.2.3. By Technology Type
  • 10.3.3. Colombia Cancer Vaccine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indication Type
      • 10.3.3.2.2. By Vaccine Type
      • 10.3.3.2.3. By Technology Type

11. Middle East and Africa Cancer Vaccine Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Indication Type
  • 11.2.2. By Vaccine Type
  • 11.2.3. By Technology Type
  • 11.2.4. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Cancer Vaccine Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Indication Type
      • 11.3.1.2.2. By Vaccine Type
      • 11.3.1.2.3. By Technology Type
  • 11.3.2. Saudi Arabia Cancer Vaccine Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Indication Type
      • 11.3.2.2.2. By Vaccine Type
      • 11.3.2.2.3. By Technology Type
  • 11.3.3. UAE Cancer Vaccine Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Indication Type
      • 11.3.3.2.2. By Vaccine Type
      • 11.3.3.2.3. By Technology Type

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

• 13.1. Recent Developments
• 13.2. Product Launches
• 13.3. Mergers & Acquisitions

14. PESTLE Analysis

15. Porter's Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Product

16. Competitive Landscape

• 16.1. Merck & Co., Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (As Reported)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. GSK plc
• 16.3. Dendreon Pharmaceuticals LLC.
• 16.4. Dynavax Technologies.
• 16.5. Ferring B.V.
• 16.6. Amgen, Inc.
• 16.7. Moderna, Inc.
• 16.8. Sanofi SA
• 16.9. AstraZeneca Pharmaceuticals LP
• 16.10. Bristol-Myers Squibb Company

17. Strategic Recommendations

18. About us & Disclaimer